ERBB2 and breast carcinoma: The involvement of Notch signalling in resistance to all types of breast cancer treatment, including chemotherapy, radiotherapy, endocrine and HER2-targeting therapies, means that Notch inhibition could be valuable in a broad range of patient groups.